Characterisation and Profiling of Standard Atopic Dermatitis Therapies in a Chronic Dermatitis Murine Model Induced by OxazoloneEXPERIMENTAL DERMATOLOGYIF3.12024-12-230PRE
Assessment of the PAR2OE+HDM Model of Atopic Dermatitis as a Therapeutic ModelJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72019-09-010OAAI
Application of reflectance confocal microscopy in the evaluation of murine healthy and lesional skinJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72019-09-010OAAI
Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M3 Receptor Antagonist/β2-Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety ProfileJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82019-07-0116OAAI
4-Amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity RelationshipsJOURNAL OF MEDICINAL CHEMISTRYIF6.82018-03-0517PREAI
Abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, has a fast association rate and long residence time at receptorEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72018-01-0110PREAI
Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β2-adrenoceptor agonist (MABA) moleculePULMONARY PHARMACOLOGY & THERAPEUTICSIF2.82017-10-0116PREAI
Short course model of oxazolone-induced dermatitis in the nape of mice: Characterisation and modulation with topical drugsJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72017-10-010OAAI
Characterization of the chloroquine-induced mouse model of pruritus using an automated behavioural systemEXPERIMENTAL DERMATOLOGYIF3.12017-08-1511PREAI
Selective Sphingosine 1-Phosphate Receptor 1 Agonist Is Protective Against Ischemia/Reperfusion in Mice选择性1-磷酸鞘氨醇受体1激动剂对小鼠缺血/再灌注的保护作用STROKEIF8.92016-12-0153OAAI
Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity RelationshipsJOURNAL OF MEDICINAL CHEMISTRYIF6.82016-11-1724PREAI
Mouse model of cutaneous adverse effects: Validation with human topical therapiesJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72016-09-010OAAI
In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterolEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72016-01-0121PREAI
Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced coughEUROPEAN RESPIRATORY JOURNALIF212015-10-304PRE
Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchiEUROPEAN JOURNAL OF PHARMACOLOGYIF4.72014-12-0179OAAI
The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromidePULMONARY PHARMACOLOGY & THERAPEUTICSIF2.82014-08-0141OAAI
Effects of Aclidinium Bromide in a Cigarette Smoke-Exposed Guinea Pig Model of Chronic Obstructive Pulmonary DiseaseAMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGYIF5.32014-02-0131PREAI
Phosphodiesterase-4 inhibitors: a review of current developments (2010-2012)EXPERT OPINION ON THERAPEUTIC PATENTSIF4.62013-05-0445PREAI
Aclidinium inhibits cigarette smoke-induced lung fibroblast-to-myofibroblast transitionEUROPEAN RESPIRATORY JOURNALIF212012-09-2737OA
Pharmacological Characterization of Abediterol, a Novel Inhaled β2-Adrenoceptor Agonist with Long Duration of Action and a Favorable Safety Profile in Preclinical ModelsJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82012-08-0142PREAI